BioSpace News Archive

Ancestry®, the global leader in family history and consumer genomics, announced it has made a $1 million educational grant to UpToDate®, a leading evidence-based clinical resource, to independently develop information for healthcare providers to help them interpret and act on the results of genetic testing

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and to increase human longevity, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine

Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, will debut the new VRNxT™ volume reduction instrument at the upcoming meeting of the Association for Molecular Pathology (AMP) in Baltimore, November 7-9, 2019.

NewLink Genetics Corporation announced it will host its third quarter 2019 conference call and webcast at 8:30 AM ET on Wednesday, November 6, 2019, to discuss its third quarter financial results and provide an update on corporate activities.

Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Tuesday, November 5, 2019 at 5pm ET to discuss third quarter 2019 financial results and provide a corporate update.

Predictive Oncology announces its placement in an editorial published by NetworkNewsWire, a multifaceted financial news and publishing company for private and public entities.

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.

Pooled efficacy and cardiovascular safety analyses from global Phase III program, and efficacy data from Phase III OLYMPUS and ROCKIES trials to be presented

IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced the appointment of Joanne Schindler, M.D., D.V.M. as its new Chief Medical Officer, effective November 4, 2019.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the third quarter of 2019 after the close of U.S. markets on Wednesday, November 6, 2019.